Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children

Pediatric Infectious Disease Journal

Volumn 39, Issue 5, 2020, Pages 355-368

  Zimmermann, Petra ^a,b,c   Curtis, Nigel ^b,c,d  

^a University of Fribourg   (Switzerland)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

epidemiology; imaging; laboratory; Middle East respiratory syndrome coronavirus; prevention; prevention, SARS CoV, MERS CoV, SARS CoV 2; severe acute respiratory syndrome coronavirus; severe acute respiratory syndrome coronavirus 2; symptoms; treatment; vaccines

Indexed keywords

DNA VACCINE; MONOCLONAL ANTIBODY; NUCLEIC ACID SYNTHESIS INHIBITOR; PROTEINASE INHIBITOR; VIRUS VACCINE;

ANIMAL; CHILD; CORONAVIRUS INFECTION; EPIDEMIC; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMIC; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS PNEUMONIA;

ANIMALS; ANTIBODIES, MONOCLONAL; CHILD; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NUCLEIC ACID SYNTHESIS INHIBITORS; PANDEMICS; PNEUMONIA, VIRAL; PROTEASE INHIBITORS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINES, DNA; VIRAL VACCINES;

EID: 85083232004     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000002660     Document Type: Article

References (246)

1. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.
2. Amer HM. Bovine-like coronaviruses in domestic and wild ruminants. Anim Health Res Rev. 2018;19:113-124.
3. Saif LJ. Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? Rev Sci Tech. 2004;23:643-660.
4. Cabeça TK, Granato C, Bellei N. Epidemiological and clinical features of human coronavirus infections among different subsets of patients. Influenza Other Respir Viruses. 2013;7:1040-1047.
5. Vabret A, Mourez T, Gouarin S, et al. An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin Infect Dis. 2003;36:985-989.
6. Esper F, Ou Z, Huang YT. Human coronaviruses are uncommon in patients with gastrointestinal illness. J Clin Virol. 2010;48:131-133.
7. Vabret A, Dina J, Gouarin S, et al. Detection of the new human coronavirus HKU1: a report of 6 cases. Clin Infect Dis. 2006;42:634-639.
8. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol. 2005;79:884-895.
9. Gorse GJ, O'Connor TZ, Hall SL, et al. Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease. J Infect Dis. 2009;199:847-857.
10. da Silva Filho LV, Zerbinati RM, Tateno AF, et al. The differential clinical impact of human coronavirus species in children with cystic fibrosis. J Infect Dis. 2012;206:384-388.
11. Chiu SS, Chan KH, Chu KW, et al. Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin Infect Dis. 2005;40:1721-1729.
12. McIntosh K, Ellis EF, Hoffman LS, et al. The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children. J Pediatr. 1973;82:578-590.
13. Woo PC, Lau SK, Lam CS, et al. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86:3995-4008.
14. Lau SK, Woo PC, Li KS, et al. Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A. J Virol. 2015;89:3076-3092.
15. Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48:2940-2947.
16. Davis BM, Foxman B, Monto AS, et al. Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding. Influenza Other Respir Viruses. 2018;12:582-590.
17. Huynh J, Li S, Yount B, et al. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol. 2012;86:12816-12825.
18. Pfefferle S, Oppong S, Drexler JF, et al. Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerg Infect Dis. 2009;15:1377-1384.
19. Corman VM, Eckerle I, Memish ZA, et al. Link of a ubiquitous human coronavirus to dromedary camels. Proc Natl Acad Sci U S A. 2016;113:9864-9869.
20. Vijgen L, Keyaerts E, Moës E, et al. Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol. 2005;79:1595-1604.
21. de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523-534.
22. Shi Z, Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 2008;133:74-87.
23. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967-1976.
24. Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis. 2005;11:1860-1865.
25. Luk HKH, Li X, Fung J, et al. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 2019;71:21-30.
26. de Groot RJ, Baker SC, Baric RS, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013;87:7790-7792.
27. Ommeh S, Zhang W, Zohaib A, et al. Genetic evidence of Middle East respiratory syndrome coronavirus (MERS-Cov) and widespread seroprevalence among camels in Kenya. Virol Sin. 2018;33:484-492.
28. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514-523.
29. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.
30. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-32. 2020. Available at: https://www.who.int/docs/defaultsource/ coronaviruse/situation-reports/20200221-sitrep-32-covid-19. pdf?sfvrsn=4802d089_2. Accessed March 2, 2020.
31. Kuypers J, Martin ET, Heugel J, et al. Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics. 2007;119:e70-e76.
32. Uddin SMI, Englund JA, Kuypers JY, et al. Burden and risk factors for coronavirus infections in infants in rural Nepal. Clin Infect Dis. 2018;67:1507-1514.
33. Taylor S, Lopez P, Weckx L, et al. Respiratory viruses and influenza-like illness: epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample. J Infect. 2017;74:29-41.
34. Fagbo SF, Garbati MA, Hasan R, et al. Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013. J Med Virol. 2017;89:195-201.
35. Zhang SF, Tuo JL, Huang XB, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. PLoS One. 2018;13:e0191789.
36. Friedman N, Alter H, Hindiyeh M, et al. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoVHKU1. Viruses. 2018;10:1-9.
37. Peak CM, Childs LM, Grad YH, et al. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci U S A. 2017;114:4023-4028.
38. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395:689-697.
39. Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med. 2015;13:210.
40. Lloyd-Smith JO, Schreiber SJ, Kopp PE, et al. Superspreading and the effect of individual variation on disease emergence. Nature. 2005;438:355-359.
41. Majumder MS, Rivers C, Lofgren E, et al. Estimation of MERScoronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data. PLoS Curr. 2014;6:1-20.
42. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol. 2004;160:509-516.
43. Chowell G, Castillo-Chavez C, Fenimore PW, et al. Model parameters and outbreak control for SARS. Emerg Infect Dis. 2004;10:1258-1263.
44. Riley S, Fraser C, Donnelly CA, et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science. 2003;300:1961-1966.
45. Lipsitch M, Cohen T, Cooper B, et al. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003;300:1966-1970.
46. Kucharski AJ, Althaus CL. The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission. Euro Surveill. 2015;20:14-18.
47. Chen SC, Chang CF, Liao CM. Predictive models of control strategies involved in containing indoor airborne infections. Indoor Air. 2006;16:469-481.
48. Cauchemez S, Nouvellet P, Cori A, et al. Unraveling the drivers of MERSCoV transmission. Proc Natl Acad Sci U S A. 2016;113:9081-9086.
49. Park JE, Jung S, Kim A, et al. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018;18:574.
50. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214-217.
51. Cyranoski D. Mystery deepens over animal source of coronavirus. 2020. Accessed March 4, 2020. Available at: https://www.nature.com/articles/ d41586-020-00548-w.
52. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2004. Available at: https:// www.who.int/csr/sars/country/table2004_04_21/en/. Accessed March 5, 2020.
53. Middle East respiratory syndrome coronavirus (MERS-CoV), MERS Monthly Summary, November 2019. https://www.who.int/emergencies/ mers-cov/en/. Accessed March 5, 2020.
54. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-48. 2020. Available at: https://www.who.int/docs/defaultsource/ coronaviruse/situation-reports/20200308-sitrep-48-covid-19. pdf?sfvrsn=16f7ccef_4. Accessed March 9, 2020.
55. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003;362:1353-1358.
56. Hunter JC, Nguyen D, Aden B, et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis. 2016;22:647-656.
57. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 2003;361:1701-1703.
58. Chiu WK, Cheung PC, Ng KL, et al. Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong. Pediatr Crit Care Med. 2003;4:279-283.
59. Bitnun A, Allen U, Heurter H, et al; Other Members of the Hospital for Sick Children SARS Investigation Team. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Pediatrics. 2003;112:e261.
60. Al-Tawfiq JA, Kattan RF, Memish ZA. Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia. World J Clin Pediatr. 2016;5:391-396.
61. Wang XF, Yuan J, Zheng YJ, et al. [Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen]. Zhonghua Er Ke Za Zhi. 2020;58:E008.
62. Lessler J, Reich NG, Brookmeyer R, et al. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9:291-300.
63. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med. 2004;141:662-673.
64. Jiang X, Rayner S, Luo MH. Does SARS-CoV-2 has a longer incubation period than SARS and MERS? J Med Virol. 2020:1-3. [Epub ahead of print]
65. Lau EH, Hsiung CA, Cowling BJ, et al. A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan. BMC Infect Dis. 2010;10:50.
66. Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8(suppl):S9-S14.
67. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752-761.
68. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the republic of Korea, 2015. Osong Public Health Res Perspect. 2015;6:269-278.
69. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386:995-1007.
70. Cowling BJ, Park M, Fang VJ, et al. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 2015;20:7-13.
71. Virlogeux V, Fang VJ, Park M, et al. Comparison of incubation period distribution of human infections with MERS-CoV in South Korea and Saudi Arabia. Sci Rep. 2016;6:35839.
72. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020. [Epub ahead of print]
73. Martin ET, Fairchok MP, Stednick ZJ, et al. Epidemiology of multiple respiratory viruses in childcare attendees. J Infect Dis. 2013;207:982-989.
74. Anderson RM, Fraser C, Ghani AC, et al. Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic. Philos Trans R Soc Lond B Biol Sci. 2004;359:1091-1105.
75. Peiris JS, Chu CM, Cheng VC, et al; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767-1772.
76. Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, et al. Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia. Front Med. 2019;13:126-130.
77. Wei M, Yuan J, Liu Y, et al. Novel coronavirus infection in hospitalized infants under 1 year of age in China. JAMA. 2020. [Epub ahead of print]
78. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med. 2004;10:368-373.
79. van der Hoek L, Sure K, Ihorst G, et al. Croup is associated with the novel coronavirus NL63. PLoS Med. 2005;2:e240.
80. Pyrc K, Berkhout B, van der Hoek L. The novel human coronaviruses NL63 and HKU1. J Virol. 2007;81:3051-3057.
81. Greenberg SB. Update on human rhinovirus and coronavirus infections. Semin Respir Crit Care Med. 2016;37:555-571.
82. McIntosh K, Kapikian AZ, Turner HC, et al. Seroepidemiologic studies of coronavirus infection in adults and children. Am J Epidemiol. 1970;91:585-592.
83. Yeh EA, Collins A, Cohen ME, et al. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. Pediatrics. 2004;113(1 pt 1):e73-e76.
84. Ge XY, Li JL, Yang XL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535-538.
85. Cheng FW, Ng PC, Chiu WK, et al. A case-control study of SARS versus community acquired pneumonia. Arch Dis Child. 2005;90:747-749.
86. Leung CW, Kwan YW, Ko PW, et al. Severe acute respiratory syndrome among children. Pediatrics. 2004;113:e535-e543.
87. Babyn PS, Chu WC, Tsou IY, et al. Severe acute respiratory syndrome (SARS): chest radiographic features in children. Pediatr Radiol. 2004;34:47-58.
88. Feng K, Yun YX, Wang XF, et al. [Analysis of CT features of 15 children with 2019 novel coronavirus infection]. Zhonghua Er Ke Za Zhi. 2020;58:E007.
89. Li AM, Ng PC. Severe acute respiratory syndrome (SARS) in neonates and children. Arch Dis Child Fetal Neonatal Ed. 2005;90:F461-F465.
90. Vabret A, Mouthon F, Mourez T, et al. Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction. J Virol Methods. 2001;97:59-66.
91. Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet. 2004;363:1699-1700.
92. Chim SS, Chiu RW, Lo YM. Genomic sequencing of the severe acute respiratory syndrome-coronavirus. Methods Mol Biol. 2006;336:177-194.
93. Chim SS, Tong YK, Hung EC, et al. Genomic sequencing of a SARS coronavirus isolate that predated the Metropole Hotel case cluster in Hong Kong. Clin Chem. 2004;50:231-233.
94. Lee JS, Ahn JS, Yu BS, et al. Evaluation of a Real-Time Reverse Transcription-PCR (RT-PCR) assay for detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in clinical samples from an outbreak in South Korea in 2015. J Clin Microbiol. 2017;55:2554-2555.
95. Kim MN, Ko YJ, Seong MW, et al. Analytical and clinical validation of six commercial Middle East respiratory syndrome coronavirus RNA detection kits based on real-time reverse-transcription PCR. Ann Lab Med. 2016;36:450-456.
96. Al Johani S, Hajeer AH. MERS-CoV diagnosis: an update. J Infect Public Health. 2016;9:216-219.
97. World Health Organization. WHO interim guidance on clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. Available at: https://apps.who.int/iris/handle/ 10665/330893. Accessed March 5, 2020.
98. Jevŝnik M, Steyer A, Zrim T, et al. Detection of human coronaviruses in simultaneously collected stool samples and nasopharyngeal swabs from hospitalized children with acute gastroenteritis. Virol J. 2013;10:46.
99. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017;3:eaao4966.
100. Chen X, Zhou B, Li M, et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis. 2004;189:1158-1163.
101. Bermingham A, Heinen P, Iturriza-Gómara M, et al. Laboratory diagnosis of SARS. Philos Trans R Soc Lond B Biol Sci. 2004;359:1083-1089.
102. Zhao LQ, Qian Y, Zhu RN, et al. [Serological analysis of SARS coronavirus in children diagnosed clinically as severe acute respiratory syndrome cases during SARS epidemic in Beijing]. Zhonghua Er Ke Za Zhi. 2006;44:262-266.
103. Müller MA, Meyer B, Corman VM, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, crosssectional, serological study. Lancet Infect Dis. 2015;15:559-564.
104. Oosterhof L, Christensen CB, Sengeløv H. Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient. Bone Marrow Transplant. 2010;45:1115-1116.
105. Cabeça TK, Bellei N. Human coronavirus NL-63 infection in a Brazilian patient suspected of H1N1 2009 influenza infection: description of a fatal case. J Clin Virol. 2012;53:82-84.
106. Munster VJ, Koopmans M, van Doremalen N, et al. A novel coronavirus emerging in China-key questions for impact assessment. N Engl J Med. 2020;382:692-694.
107. Jia N, Feng D, Fang LQ, et al. Case fatality of SARS in mainland China and associated risk factors. Trop Med Int Health. 2009;14(suppl 1):21-27.
108. Nassar MS, Bakhrebah MA, Meo SA, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22:4956-4961.
109. Aleanizy FS, Mohmed N, Alqahtani FY, et al. Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study. BMC Infect Dis. 2017;17:23.
110. Alhamlan FS, Majumder MS, Brownstein JS, et al. Case characteristics among Middle East respiratory syndrome coronavirus outbreak and non-outbreak cases in Saudi Arabia from 2012 to 2015. BMJ Open. 2017;7:e011865.
111. World Health Organization. Disease outbreak news. 24 February 2020. Middle East respiratory syndrome coronavirus (MERS-CoV)-The Kingdom of Saudi Arabia. Available at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/. Accessed March 5, 2020.
112. Oh MD, Park WB, Park SW, et al. Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J Intern Med. 2018;33:233-246.
113. National Health Commission of the People's Republic of China. 2020. Available at: http://www.nhc.gov.cn/xcs/yqtb/202002/6c305f6d70f545d59 548ba17d79b8229.shtml. Accessed February 15 2020.
114. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020. [Epub ahead of print]
115. Isaacs D, Flowers D, Clarke JR, et al. Epidemiology of coronavirus respiratory infections. Arch Dis Child. 1983;58:500-503.
116. Monto AS, Lim SK. The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection. J Infect Dis. 1974;129:271-276.
117. Dijkman R, Jebbink MF, El Idrissi NB, et al. Human coronavirus NL63 and 229E seroconversion in children. J Clin Microbiol. 2008;46:2368-2373.
118. Hasony HJ, Macnaughton MR. Prevalence of human coronavirus antibody in the population of southern Iraq. J Med Virol. 1982;9:209-216.
119. Kaye HS, Marsh HB, Dowdle WR. Seroepidemiologic survey of coronavirus (strain OC 43) related infections in a children's population. Am J Epidemiol. 1971;94:43-49.
120. Leung TF, Li CY, Lam WY, et al. Epidemiology and clinical presentations of human coronavirus NL63 infections in hong kong children. J Clin Microbiol. 2009;47:3486-3492.
121. Jin Y, Zhang RF, Xie ZP, et al. Newly identified respiratory viruses associated with acute lower respiratory tract infections in children in Lanzou, China, from 2006 to 2009. Clin Microbiol Infect. 2012;18:74-80.
122. Wu PS, Chang LY, Berkhout B, et al. Clinical manifestations of human coronavirus NL63 infection in children in Taiwan. Eur J Pediatr. 2008;167:75-80.
123. Lina B, Valette M, Foray S, et al. Surveillance of community-acquired viral infections due to respiratory viruses in Rhone-Alpes (France) during winter 1994 to 1995. J Clin Microbiol. 1996;34:3007-3011.
124. Lau SK, Woo PC, Yip CC, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol. 2006;44:2063-2071.
125. Guan Y, Peiris JS, Zheng B, et al. Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome. Lancet. 2004;363:99-104.
126. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1977-1985.
127. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12:222.
128. Breban R, Riou J, Fontanet A. Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet. 2013;382:694-699.
129. Cristallo A, Gambaro F, Biamonti G, et al. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. New Microbiol. 1997;20:105-114.
130. Dessau RB, Lisby G, Frederiksen JL. Coronaviruses in spinal fluid of patients with acute monosymptomatic optic neuritis. Acta Neurol Scand. 1999;100:88-91.
131. Shimizu C, Shike H, Baker SC, et al. Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease. J Infect Dis. 2005;192:1767-1771.
132. Chang LY, Chiang BL, Kao CL, et al; Kawasaki Disease Research Group. Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan. J Infect Dis. 2006;193:283-286.
133. Chu CM, Poon LL, Cheng VC, et al. Initial viral load and the outcomes of SARS. CMAJ. 2004;171:1349-1352.
134. Chen WJ, Yang JY, Lin JH, et al. Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. Clin Infect Dis. 2006;42:1561-1569.
135. van Elden LJ, van Loon AM, van Alphen F, et al. Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction. J Infect Dis. 2004;189:652-657.
136. Li AM, So HK, Chu W, et al. Radiological and pulmonary function outcomes of children with SARS. Pediatr Pulmonol. 2004;38:427-433.
137. Shek CC, Ng PC, Fung GP, et al. Infants born to mothers with severe acute respiratory syndrome. Pediatrics. 2003;112:e254.
138. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191:292-297.
139. Saeed AA, Abedi GR, Alzahrani AG, et al. Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015-February 2016. Emerg Infect Dis. 2017;23:682-685.
140. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, et al. Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Clin Microbiol Infect. 2014;20:469-474.
141. Payne DC, Iblan I, Alqasrawi S, et al; Jordan MERS-CoV Investigation Team. Stillbirth during infection with Middle East respiratory syndrome coronavirus. J Infect Dis. 2014;209:1870-1872.
142. Alserehi H, Wali G, Alshukairi A, et al. Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infect Dis. 2016;16:105.
143. Malik A, El Masry KM, Ravi M, et al. Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013. Emerg Infect Dis. 2016;22:515-517.
144. Assiri A, Abedi GR, Al Masri M, et al. Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia. Clin Infect Dis. 2016;63:951-953.
145. Centers for Disease Control and Prevention CfDCaP. Evaluating and reporting persons under investigation (PUI). 2020. Available at: https://www.cdc.gov/ coronavirus/2019-nCoV/hcp/clinical-criteria.html. Accessed March 5, 2020.
146. World Health Organization. Global Surveillance for human infection with novel coronavirus (2019-nCoV). 2020. Available at: https://www. who.int/publications-detail/global-surveillance-for-human-infection-withnovel-coronavirus-(2019-ncov) and https://www.ecdc.europa.eu/en/casedefinition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov. Accessed March 5, 2020.
147. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.
148. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020:1-7. [Epub ahead of print]
149. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis. 2014;210:1590-1594.
150. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004;10:1550-1557.
151. Che XY, Qiu LW, Liao ZY, et al. Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43. J Infect Dis. 2005;191:2033-2037.
152. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.
153. Cheng VC, Chan JF, To KK, et al. Clinical management and infection control of SARS: lessons learned. Antiviral Res. 2013;100:407-419.
154. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9:399-406.
155. Chu CM, Cheng VC, Hung IF, et al; HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252-256.
156. Ng PC, Lam CW, Li AM, et al. Inflammatory cytokine profile in children with severe acute respiratory syndrome. Pediatrics. 2004;113(1 pt 1):e7-e14.
157. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14:1090-1095.
158. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-2a or IFN-1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70:2129-2132.
159. Al-Tawfiq JA, Momattin H, Dib J, et al. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42-46.
160. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67:606-616.
161. Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212:1904-1913.
162. AlGhamdi M, Mushtaq F, Awn N, et al. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant. 2015;15:1101-1104.
163. Centers for Disease Control and Prevention CfDCaP. Interim clinical guidance for management of patients with confirmed 2019 novel coronavirus (2019-nCoV) infection. 2020. Available at: https://www.cdc.gov/ coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed February 21, 2010.
164. Zumla A, Chan JF, Azhar EI, et al. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327-347.
165. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44-46.
166. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6:234ra59.
167. Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014;88:7796-7805.
168. Tang XC, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A. 2014;111:E2018-E2026.
169. Channappanavar R, Lu L, Xia S, et al. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis. 2015;212:1894-1903.
170. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676-678.
171. Pang H, Liu Y, Han X, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol. 2004;85(pt 10):3109-3113.
172. Barton C, Kouokam JC, Lasnik AB, et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014;58:120-127.
173. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.
174. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251-254.
175. Huang X, Dong W, Milewska A, et al. Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J Virol. 2015;89:7202-7213.
176. Vijgen L, Keyaerts E, Zlateva K, et al. Identification of six new polymorphisms in the human coronavirus 229E receptor gene (aminopeptidase N/ CD13). Int J Infect Dis. 2004;8:217-222.
177. Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87:12552-12561.
178. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76-84.
179. Kawase M, Shirato K, van der Hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86:6537-6545.
180. Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papainlike protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21-38.
181. Ratia K, Pegan S, Takayama J, et al. A noncovalent class of papain-like protease/ deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008;105:16119-16124.
182. Lee H, Lei H, Santarsiero BD, et al. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem Biol. 2015;10:1456-1465.
183. Savarino A, Di Trani L, Donatelli I, et al. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6:67-69.
184. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
185. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020:269-271. [Epub ahead of print]
186. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508:402-405.
187. Adedeji AO, Singh K, Kassim A, et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother. 2014;58:4894-4898.
188. Lundin A, Dijkman R, Bergström T, et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus. PLoS Pathog. 2014;10:e1004166.
189. Rappe JCF, de Wilde A, Di H, et al. Antiviral activity of K22 against members of the order Nidovirales. Virus Res. 2018;246:28-34.
190. Rider TH, Zook CE, Boettcher TL, et al. Broad-spectrum antiviral therapeutics. PLoS One. 2011;6:e22572.
191. He Y, Li J, Du L, et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006;24:5498-5508.
192. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24:490-502.
193. Kim DW, Kim YJ, Park SH, et al. Variations in spike glycoprotein gene of MERS-CoV, South Korea, 2015. Emerg Infect Dis. 2016;22:100-104.
194. Sohrab SS, Azhar EI. Genetic diversity of MERS-CoV spike protein gene in Saudi Arabia. J Infect Public Health. 2019. [Epub ahead of print]
195. He Y, Zhou Y, Siddiqui P, et al. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun. 2004;325:445-452.
196. Hashem AM, Algaissi A, Agrawal AS, et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model. J Infect Dis. 2019;220:1558-1567.
197. Czub M, Weingartl H, Czub S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23:2273-2279.
198. DeDiego ML, Alvarez E, Almazán F, et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol. 2007;81:1701-1713.
199. Lamirande EW, DeDiego ML, Roberts A, et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol. 2008;82:7721-7724.
200. Dediego ML, Pewe L, Alvarez E, et al. Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. Virology. 2008;376:379-389.
201. Yount B, Roberts RS, Sims AC, et al. Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol. 2005;79:14909-14922.
202. de Haan CA, Masters PS, Shen X, et al. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology. 2002;296:177-189.
203. Almazán F, DeDiego ML, Sola I, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. mBio. 2013;4:e00650-e00613.
204. Menachery VD, Gralinski LE, Mitchell HD, et al. Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis. mSphere. 2017;2:e00346-e00417.
205. Xiong S, Wang YF, Zhang MY, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett. 2004;95:139-143.
206. Takasuka N, Fujii H, Takahashi Y, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004;16:1423-1430.
207. Spruth M, Kistner O, Savidis-Dacho H, et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine. 2006;24:652-661.
208. Deng Y, Lan J, Bao L, et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect. 2018;7:60.
209. Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12:2351-2356.
210. Lin JT, Zhang JS, Su N, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12:1107-1113.
211. Zhou J, Wang W, Zhong Q, et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine. 2005;23:3202-3209.
212. Jaume M, Yip MS, Kam YW, et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med J. 2012;18(suppl 2):31-36.
213. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226-236.
214. Adney DR, Wang L, van Doremalen N, et al. Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses. 2019;11:E212.
215. Wang Y, Tai W, Yang J, et al. Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017;13:1615-1624.
216. Tai W, Zhao G, Sun S, et al. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016;499:375-382.
217. Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32:2100-2108.
218. Lan J, Yao Y, Deng Y, et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2:1438-1446.
219. Jiaming L, Yanfeng Y, Yao D, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine. 2017;35:10-18.
220. Zhang N, Channappanavar R, Ma C, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016;13:180-190.
221. Chen WH, Du L, Chag SM, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014;10:648-658.
222. Zakhartchouk AN, Viswanathan S, Mahony JB, et al. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. J Gen Virol. 2005;86(pt 1):211-215.
223. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362:1895-1896.
224. Munster VJ, Wells D, Lambe T, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines. 2017;2:28.
225. Rocha CD, Caetano BC, Machado AV, et al. Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol. 2004;7:83-94.
226. Hill, A. Safety and immunogenicity of a candidate MERS-CoV vaccine (MERS001). 2018. Available at: https://clinicaltrials.gov/ct2/show/study/ NCT03399578. Accessed February 22, 2020.
227. See RH, Zakhartchouk AN, Petric M, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol. 2006;87(pt 3):641-650.
228. Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A. 2004;101:6641-6646.
229. Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A. 2004;101:9804-9809.
230. Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363:2122-2127.
231. Liniger M, Zuniga A, Tamin A, et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine. 2008;26:2164-2174.
232. Faber M, Lamirande EW, Roberts A, et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol. 2005;86(pt 5):1435-1440.
233. Luo F, Feng Y, Liu M, et al. Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination. Clin Vaccine Immunol. 2007;14:990-997.
234. Wang L, Shi W, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712.
235. Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus antispike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7:301ra132.
236. Modjarrad, K. Phase I, open label dose ranging safety study of GLS-5300 in healthy volunteers. 2016. Available at: https://clinicaltrials.gov/ct2/ show/NCT02670187?term=GLS-5300. Accessed February 22, 2020.
237. Maslow, J. Evaluate the safety, tolerability and immunogenicity study of GLS-5300 in healthy volunteers. 2018. Available at: https://clinicaltrials. gov/ct2/show/NCT03721718. Accessed February 22, 2020.
238. Addo, M. Safety, tolerability and immunogenicity of vaccine candidate MVA-MERS-S. 2018. Available at: https://clinicaltrials.gov/ct2/show/ NCT03615911#outcomemeasures. Accessed February 22, 2020.
239. Bin SY, Heo JY, Song MS, et al. Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea. Clin Infect Dis. 2016;62:755-760.
240. Ng PC, So KW, Leung TF, et al. Infection control for SARS in a tertiary neonatal centre. Arch Dis Child Fetal Neonatal Ed. 2003;88:F405-F409.
241. Leung TF, Ng PC, Cheng FW, et al. Infection control for SARS in a tertiary paediatric centre in Hong Kong. J Hosp Infect. 2004;56:215-222.
242. Dowell SF, Simmerman JM, Erdman DD, et al. Severe acute respiratory syndrome coronavirus on hospital surfaces. Clin Infect Dis. 2004;39:652-657.
243. Otter JA, Donskey C, Yezli S, et al. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect. 2016;92:235-250.
244. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. J Hosp Infect. 2020:246-251. [Epub ahead of print]
245. Ijaz MK, Brunner AH, Sattar SA, et al. Survival characteristics of airborne human coronavirus 229E. J Gen Virol. 1985;66(pt 12):2743-2748.
246. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. medRxiv 2020. Available at: https://doi.org/10.1101/2020.03.03.20028423. Accessed March 4, 2020.